FME Stock Overview
Provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 5/6 |
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
Fresenius Medical Care AG Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | €44.16 |
| 52 Week High | €46.20 |
| 52 Week Low | €32.51 |
| Beta | 0.84 |
| 1 Month Change | 6.15% |
| 3 Month Change | 15.09% |
| 1 Year Change | 16.33% |
| 3 Year Change | -22.42% |
| 5 Year Change | -32.08% |
| Change since IPO | 169.54% |
Recent News & Updates
Here's What's Concerning About Fresenius Medical Care's (ETR:FME) Returns On Capital
Dec 22
What Is Fresenius Medical Care AG's (ETR:FME) Share Price Doing?
Nov 21Recent updates
Here's What's Concerning About Fresenius Medical Care's (ETR:FME) Returns On Capital
Dec 22What Is Fresenius Medical Care AG's (ETR:FME) Share Price Doing?
Nov 21Fresenius Medical Care AG (ETR:FME) Not Flying Under The Radar
Nov 01We Think Fresenius Medical Care (ETR:FME) Is Taking Some Risk With Its Debt
Sep 26These Return Metrics Don't Make Fresenius Medical Care (ETR:FME) Look Too Strong
Sep 08At €34.34, Is Fresenius Medical Care AG (ETR:FME) Worth Looking At Closely?
Aug 20Fresenius Medical Care AG Earnings Missed Analyst Estimates: Here's What Analysts Are Forecasting Now
Aug 02These 4 Measures Indicate That Fresenius Medical Care (ETR:FME) Is Using Debt Extensively
Jun 17What You Can Learn From Fresenius Medical Care AG's (ETR:FME) P/E
May 30Some Shareholders May Object To A Pay Rise For Fresenius Medical Care AG's (ETR:FME) CEO This Year
May 10Fresenius Medical Care (ETR:FME) Is Increasing Its Dividend To €1.19
Apr 26Fresenius Medical Care's (ETR:FME) Shareholders Will Receive A Bigger Dividend Than Last Year
Mar 29Fresenius Medical Care (ETR:FME) Has Announced That It Will Be Increasing Its Dividend To €1.19
Mar 14Fresenius Medical Care's (ETR:FME) Dividend Will Be Increased To €1.19
Feb 23When Should You Buy Fresenius Medical Care AG (ETR:FME)?
Feb 22Market Participants Recognise Fresenius Medical Care AG's (ETR:FME) Earnings
Feb 03Fresenius Medical Care (ETR:FME) Could Be Struggling To Allocate Capital
Jan 16Shareholder Returns
| FME | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 1.4% | 0.7% | 0.6% |
| 1Y | 16.3% | 18.0% | 7.2% |
Return vs Industry: FME underperformed the German Healthcare industry which returned 18% over the past year.
Return vs Market: FME exceeded the German Market which returned 7.2% over the past year.
Price Volatility
| FME volatility | |
|---|---|
| FME Average Weekly Movement | 4.0% |
| Healthcare Industry Average Movement | 4.8% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FME has not had significant price volatility in the past 3 months compared to the German market.
Volatility Over Time: FME's weekly volatility (4%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 113,079 | Helen Giza | www.freseniusmedicalcare.com |
Fresenius Medical Care AG provides dialysis and related services for individuals with renal diseases in Germany, North America, and internationally. The company offers dialysis treatment and related laboratory and diagnostic services through a network of outpatient dialysis clinics; materials, training, and patient support services comprising clinical monitoring, follow-up assistance, and arranging for delivery of the supplies to the patient’s residence; and dialysis services under contract to hospitals in the United States for the hospitalized end-stage renal disease (ESRD) patients and for patients suffering from acute kidney failure. It also develops, manufactures, and distributes various health care products, including polysulfone dialyzers, hemodialysis machines, peritoneal dialysis cyclers, peritoneal dialysis solutions, hemodialysis concentrates, solutions and granulates, bloodlines, renal pharmaceuticals, systems for water treatment, and acute cardiopulmonary and apheresis products.
Fresenius Medical Care AG Fundamentals Summary
| FME fundamental statistics | |
|---|---|
| Market cap | €12.96b |
| Earnings (TTM) | €658.94m |
| Revenue (TTM) | €19.24b |
19.7x
P/E Ratio0.7x
P/S RatioIs FME overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FME income statement (TTM) | |
|---|---|
| Revenue | €19.24b |
| Cost of Revenue | €14.40b |
| Gross Profit | €4.84b |
| Other Expenses | €4.18b |
| Earnings | €658.94m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
Feb 25, 2025
| Earnings per share (EPS) | 2.25 |
| Gross Margin | 25.14% |
| Net Profit Margin | 3.43% |
| Debt/Equity Ratio | 49.4% |
How did FME perform over the long term?
See historical performance and comparisonDividends
2.7%
Current Dividend Yield53%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/30 00:47 |
| End of Day Share Price | 2024/12/30 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Fresenius Medical Care AG is covered by 58 analysts. 18 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Martin Schnee | AlphaValue |
| Brian Williams | Avondale Partners |
| Olav Zilian | Baader Helvea Equity Research |